Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/TMI and ASCT for High-Risk Myeloma
NCT03100877Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Jan 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by City of Hope. Planned start Jan 2018; status: withdrawn.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT03100877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100877.